B. Riley lowered the firm’s price target on MediciNova (MNOV) to $5 from $6 and keeps a Buy rating on the shares. The firm points out the company’s current cash on hand of $37M implies a runway into 2027. It updated MediciNova’s model, now exclusively focused on amyotrophic lateral sclerosis-related risk-adjusted revenue and spending.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.